First-day step-down to oral outpatient treatment versus continued standard treatment in children with cancer and low-risk fever in neutropenia. A randomized controlled trial within the multicenter SPOG 2003 FN study

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 423-430

  Brack, Eva ^a   Bodmer, Nicole ^b   Simon, Arne ^c   Leibundgut, Kurt ^a   Kühne, Thomas ^d   Niggli, Felix K ^b   Ammann, Roland A ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Fever in neutropenia; Low risk; Non inferiority; Step down

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN;

ADENOVIRUS INFECTION; ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHEMOTHERAPY INDUCED NEUTROPENIC FEVER; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; NONMYELOABLATIVE CONDITIONING; OUTPATIENT CARE; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; AMBULATORY CARE; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; MALE; NEUTROPENIA; RISK;

EID: 84861097138     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24076     Document Type: Article

References (43)

1. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Talcott JA, Siegel RD, Finberg R, et al. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 1992; 10: 316-322.
3. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18: 3038-3051.
4. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 2010; 21: v252-v256.
5. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-e93.
6. Holdsworth MT, Hanrahan J, Albanese B, et al. Outpatient management of febrile neutropenia in children with cancer. Pediatr Drugs 2003; 5: 443-455.
7. Ammann RA, Simon A, de Bont ESJM. Low risk episodes of fever and neutropenia in pediatric oncology: Is outpatient oral antibiotic therapy the new gold standard of care? Pediatr Blood Cancer 2005; 45: 244-247.
8. Härtel C, Deuster M, Lehrnbecher T, et al. Current approaches for risk stratification of infectious complications in pediatric oncology. Pediatr Blood Cancer 2007; 49: 767-773.
9. te Poele EM, Tissing WJE, Kamps WA, et al. Risk assessment in fever and neutropenia in children with cancer: What did we learn? Crit Rev Oncol Hematol 2009; 72: 45-55.
10. Boragina M, Patel H, Reiter S, et al. Management of febrile neutropenia in pediatric oncology patients: A Canadian survey. Pediatr Blood Cancer 2007; 48: 521-526.
11. Phillips B, Selwood K, Lane SM, et al. Variation in policies for the management of febrile neutropenia in United Kingdom Children's Cancer Study Group centers. Arch Dis Child 2007; 92: 495-498.
12. Mullen CA, Petropoulos D, Roberts WM, et al. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer 1999; 86: 126-134.
13. Petrilli AS, Dantas LS, Campos MC, et al. Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: Randomized prospective trial. Med Pediatr Oncol 2000; 34: 87-91.
14. Paganini H, Gomez S, Ruvinsky S, et al. Outpatient, sequential, parenteral-oral antibiotic therapy for lower risk febrile neutropenia in children with malignant disease. Cancer 2003; 97: 1775-1780.
15. Gupta A, Swaroop C, Agarwala S, et al. Randomized controlled trial comparing oral amoxicillin-clavulanate and ofloxacin with intravenous ceftriaxone and amikacin as outpatient therapy in pediatric low-risk febrile neutropenia. J Pediatr Hematol Oncol 2009; 31: 635-641.
16. Teuffel O, Ethier MC, Alibhai SM, et al. Outpatient management of cancer patients with febrile neutropenia: A systematic review and meta-analysis. Ann Oncol 2011; 22: 2358-2365.
17. Alexander SW, Walsh TJ, Freifeld AG, et al. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2002. pp. 1239-1283.
18. Ammann RA, Bodmer N, Hirt A, et al. Predicting adverse events in children with fever and chemotherapy-induced neutropenia: The prospective multicenter SPOG 2003 FN study. J Clin Oncol 2010; 28: 2008-2014.
19. Elting LS. Stratification in clinical trials of febrile neutropenia. Support Care Cancer 1998; 6: 457-461.
20. Altman DG. Practical statistics for medical research. London: Chapman & Hall; 1991. p. 611.
21. Aquino VM, Herrera L, Sandler ES, et al. Feasibility of oral ciprofloxacin for the outpatient management of febrile neutropenia in selected children with cancer. Cancer 2000; 88: 1710-1714.
22. Park JR, Coughlin J, Hawkins D, et al. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients. Med Pediatr Oncol 2003; 40: 93-98.
23. Feld R. Methodology for clinical trials in cancer patients with febrile neutropenia. Do we have a consensus? Support Care Cancer 1998; 6: 423-424.
24. Lüthi F, Leibundgut K, Niggli FK, et al. Serious medical complications in children with cancer and fever in chemotherapy-induced neutropenia: Results of the prospective multicenter SPOG 2003 FN study. Pediatr Blood Cancer. DOI: 10.1002/pbc.23277.
25. Kern WV, Cometta A, De Bock R, et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1999; 341: 312-318.
26. Piaggio G, Elbourne DR, Altman DG, et al. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA 2006; 295: 1152-1160.
27. Chan ISF. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. Stat Med 1998; 17: 1403-1413.
28. Cytel Inc. Two independent binomial samples. In: StatXact 8 user manual. Cambridge, MA: Cytel Inc.; 2007. pp. 381-466.
29. Wiens BL. Choosing an equivalence limit for noninferiority or equivalence studies. Control Clin Trials 2002; 23: 2-14.
30. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. Boca Raton, London, New York, Washington, DC: Chapman & Hall/CRC; 1999. p. 390.
31. Klaassen RJ, Goodman TR, Pham B, et al. "Low-risk" prediction rule for pediatric oncology patients presenting with fever and neutropenia. J Clin Oncol 2000; 18: 1012-1019.
32. Ammann RA, Hirt A, Ridolfi Lüthy A, et al. Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. Med Pediatr Oncol 2003; 41: 436-443.
33. Ammann RA, Hirt A, Ridolfi Lüthy A, et al. Predicting bacteremia in children with fever and chemotherapy-induced neutropenia. Pediatr Infect Dis J 2004; 23: 61-67.
34. Lucas KG, Brown AE, Armstrong D, et al. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996; 77: 791-798.
35. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005; 6: 2-8.
36. Steiner I, Aebi C, Ridolfi Lüthy A, et al. Fatal adenovirus hepatitis during maintenance therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50: 647-649.
37. Santolaya ME, Alvarez AM, Aviles CL, et al. Admission clinical and laboratory factors associated with death in children with cancer during a febrile neutropenic episode. Pediatr Infect Dis J 2007; 26: 794-798.
38. Santolaya ME, Alvarez AM, Aviles CL, et al. Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: A prospective, multicenter trial. Pediatr Infect Dis J 2008; 27: 538-543.
39. Teuffel O, Amir E, Alibhai SM, et al. Cost-effectiveness of outpatient management for febrile neutropenia in children with cancer. Pediatrics 2011; 127: e279-e286.
40. Sung L, Feldman BM, Schwamborn G, et al. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: Measuring parents' and healthcare professionals' preferences. J Clin Oncol 2004; 22: 3922-3929.
41. Quezada G, Sunderland T, Chan KW, et al. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. Pediatr Blood Cancer 2007; 48: 273-277.
42. Cheng S, Teuffel O, Ethier MC, et al. Health-related quality of life anticipated with different management strategies for paediatric febrile neutropaenia. Br J Cancer 2011; 105: 606-611.
43. Phillips B, Wade R, Stewart LA, et al. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer 2010; 46: 2950-2964.